Opaleye Management’s NextCure NXTC Stock Holding History

Opaleye Management’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-141,181	Closed	-$1.51M	–	62
2026 Q1	$1.51M	Buy	+141,181	New	+$1.72M	0.2%	48
2019 Q4	–	Sell	-7,083	Closed	-$2.62M	–	50
2019 Q3	$2.62M	Buy	+7,083	New	+$2.3M	0.95%	36

Other funds holding NXTC

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Verdad Advisers Boston, Massachusetts $104M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Opaleye Management's NXTC Position: Q2 2026 in Review

Opaleye Management sold out of NextCure (NXTC) in Q2 2026, closing a stake of 141,181 shares — an estimated $1.51M sold.

Opaleye Management first reported a position in NXTC in Q3 2019 and held it in 2 quarters. The position peaked at $2.62M in Q3 2019. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

Opaleye Management reported no remaining NextCure position as of Q2 2026 after selling out during the quarter.
Opaleye Management sold 141,181 NextCure shares in Q2 2026, an estimated $1.51M.
Opaleye Management first reported a position in NextCure in Q3 2019 and held it in 2 quarters.
Opaleye Management's NextCure position peaked at $2.62M in Q3 2019.
30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.